Destiny Pharma PLC
LSE:DEST
EV/OCF
Enterprise Value to OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
Market Cap | EV/OCF | ||||
---|---|---|---|---|---|
UK |
Destiny Pharma PLC
LSE:DEST
|
15.3m GBP | -1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
288.5B USD | 14.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
171.3B USD | 27.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 28.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.5B USD | 21 | ||
AU |
CSL Ltd
ASX:CSL
|
136.7B AUD | 37.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.4B USD | 10 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
49B USD | -14.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -77.6 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 24.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.6T KRW | 75.5 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.